Syndel's fish anesthetic approved in the UK
Syndel’s tricaine methanesulfonate fish anesthetic received Marketing Authorization from the United Kingdom’s Veterinary Medicines Directorate (VMD) on March 22, 2022.
Syndel’s tricaine methanesulfonate (MS-222) fish anesthetic, Syncaine®, received Marketing Authorization from the United Kingdom’s Veterinary Medicines Directorate (VMD) on March 22, 2022.
Syncaine®, formally known as Tricaine-S and Aqualife TMS, is manufactured at Syndel’s new US production facility. Since its initial US FDA approval in 1997, Syndel’s Tricaine has become a recognized and highly regarded fish anesthetic that is widely used in the global aquaculture industry.
Founded in 1972, Syndel is dedicated to delivering fish health solutions for the aquaculture industry. From Syndel’s head office located in Ferndale, Washington, USA, Syndel manufactures and markets a portfolio of products that are specifically dedicated to fish health, nutrition, reproduction, and biosecurity.
For more information, please visit www.syndel.com or contact us at firstname.lastname@example.org.